The IPO pricing and demand will be the key near-term catalyst. Monitor the final IPO price relative to the $14-$16 range and the underwriters' exercise of the greenshoe option. Post-IPO, focus on enrollment updates for the SURPASS registrational trial (expected completion H2 2027) and initial data readouts for ipsoprubart in T/NK cell malignancies and ELA822 in healthy volunteers (both H1 2027).
Executive Summary
Electra Therapeutics, a late clinical-stage biopharmaceutical company, filed Amendment No. 1 to its S-1 registration statement for an IPO of 21,666,667 shares of common stock at an expected price range of $14.00 to $16.00 per share. The company is developing precision medicines targeting SIRP proteins for immune-mediated diseases and cancer, with its lead candidate ipsoprubart in a global registrational trial for sHLH. The IPO is critical to resolve a going-concern doubt, with net proceeds of approximately $296.6 million (at the midpoint) expected to fund operations into 2029, primarily advancing ipsoprubart and ELA822 through clinical development.
Key Financial Metrics
Key Facts
- Offering 21,666,667 shares at $14.00-$16.00 per share.
- Net proceeds estimated at ~$296.6M at the $15.00 midpoint.
- Lead candidate ipsoprubart is in a global Phase 2/3 registrational trial for sHLH.
- Company had an accumulated deficit of $221.9M as of June 30, 2026.
- Existing cash, cash equivalents, and marketable securities were $97.7M as of June 30, 2026.
- Pro forma as adjusted cash, cash equivalents, and marketable securities would be ~$394.3M.
- Company has concluded there is substantial doubt about its ability to continue as a going concern without the IPO proceeds.
- Ipsoprubart has Breakthrough Therapy designation from the FDA and PRIME designation from the EMA.
- Second product candidate ELA822 initiated a Phase 1 trial in healthy volunteers in Europe in August 2026.
- Underwriters have a 30-day option to purchase up to an additional 3,250,000 shares.
Financial Impact
IPO expected to raise ~$296.6M in net proceeds (at $15.00 midpoint), increasing pro forma as adjusted cash to ~$394.3M from $97.7M. Net loss was $48.9M for H1 2026 and $62.0M for FY 2025. Accumulated deficit of $221.9M as of June 30, 2026.
Risk Factors
- Clinical trial failure: ipsoprubart may not meet endpoints in the registrational SURPASS trial.
- Regulatory risk: FDA/EMA may not accept the single-arm trial design with external control comparator.
- Commercial risk: No approved therapies for sHLH broadly; market adoption is uncertain.
- Financial risk: Company has a history of losses and will need additional capital beyond IPO proceeds to complete development and commercialization.
- Manufacturing risk: Reliance on third-party manufacturers, including a CMO with an FDA OAI classification.
- Competition: Off-label therapies and potential future competitors in sHLH and T/NK cell malignancies.
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001193125-26-389755 |
| Document: d61940dex11.htm | 0001193125-26-389755 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | SC 13G | $11.35 $11.25 | ▼ −0.88% | ▼ −0.68% | $8.37 (−26.26%) |
Sep 28, 2026 28d ago | SC 13G | $11.35 $11.25 | ▼ −0.88% | ▼ −0.68% | $8.37 (−26.26%) |
Sep 25, 2026 4w ago | SC 13D | $11.32 $11.35 | ▲ +0.27% | ▲ +0.45% | $8.37 (−26.06%) |
Sep 23, 2026 4w ago | Insider Cluster | $11.82 $11.55 | ▼ −2.28% | ▼ −2.83% | $8.37 (−29.19%) |
Sep 21, 2026 5w ago | 3 | $13.62 $12.67 | ▼ −6.97% | ▼ −6.25% | $8.37 (−38.55%) |
Sep 18, 2026 5w ago | 424B4 | $13.92 $13.62 | ▼ −2.16% | ▼ −2.14% | $8.37 (−39.87%) |
Sep 18, 2026 5w ago | 3 | $13.92 $13.62 | ▼ −2.16% | ▼ −2.14% | $8.37 (−39.87%) |
Sep 18, 2026 5w ago | 3 | $13.92 $13.62 | ▼ −2.16% | ▼ −2.14% | $8.37 (−39.87%) |
Sep 18, 2026 5w ago | 3 | $13.92 $13.62 | ▼ −2.16% | ▼ −2.14% | $8.37 (−39.87%) |
Sep 18, 2026 5w ago | EFFECT | $13.25 $13.92 | ▲ +5.06% | ▲ +3.51% | $8.37 (−36.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers